Associated Papers
Plasma thrombin-activatable fibrinolysis inhibitor and the 1040C/T polymorphism are risk factors for diabetic kidney disease in Chinese patients with type 2 diabetes.
Huang Q et al.
Peerj, 2023
Association between polymorphisms in the flanking region of the TAFI gene and atherosclerotic cerebral infarction in a Chinese population.
Li Y et al.
Lipids in Health and Disease, 2014
Thrombin-activatable fibrinolysis inhibitor polymorphisms and recurrent pregnancy loss.
Masini S et al.
Fertility and Sterility, 2009
Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men.
Meltzer ME et al.
Haematologica, 2009
A new functional assay of thrombin activatable fibrinolysis inhibitor.
Guimarães AH et al.
Journal of Thrombosis and Haemostasis : Jth, 2005
Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays.
Guimarães AH et al.
British Journal of Haematology, 2004
A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels.
Brouwers GJ et al.
Blood, 2001
Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis.
Franco RF et al.
Haematologica, 2001
Genetic aspects of ischemic stroke: coagulation, homocysteine, and lipoprotein metabolism as potential risk factors.
Stankovic S et al.
Critical Reviews in Clinical Laboratory Sciences, 0
Select a paper to view details